IMDX
Insight Molecular Diagnostics Inc.
$5.72
+9.16%
$184.7M
No data for this timeframe.
Vol
Market Cap$184.7M
Cap SizeMicro Cap
Inst. Holders4 funds
Inst. Value$4.3M
Inst. Activity0 buys / 2 sells
Insider Activity7B / 0S
Insider Net $$5.7M
Press Releases1
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. CA·CIK 0001642380·Prev Close $5.24
Recent Activity
Apr 27, 2026
Insider
BROADWOOD PARTNERS, L.P. bought 250,923 shares
10%+ Owner @ $3.64 ($913.1K)
Apr 24, 2026
Insider
BROADWOOD PARTNERS, L.P. bought 38,880 shares
10%+ Owner @ $3.53 ($137.1K)
Apr 23, 2026
Insider
BROADWOOD PARTNERS, L.P. bought 280,381 shares
10%+ Owner @ $3.50 ($982.0K)
Inst.
MORGAN STANLEY — TRIM
35,913 shares ($269.3K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
13,400 shares ($100.5K)
Jun 9, 2026
other
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
<p>NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq
Mar 26, 2026
Press
Insight Molecular Diagnostics (IMDX) reported strong revenue growth for 2025, submitted its GraftAssureDx kidney transpl
Impact 8/10
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$8.33 (Feb 2026)
Current $5.85
Low $4.00
Median $9.00
High $12.00
3 analysts
$4.00
$12.00
Analyst Ratings
2Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 17, 2026 | Lake Street | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 | $-0.23 — $-0.23 | 23% YoY | 1 |
| Next Q | $-0.18 | $-0.18 — $-0.18 | 23% YoY | 1 |
| Current FY | $-0.85 | $-0.85 — $-0.85 | 1 | |
| Next FY | $-0.78 | $-0.78 — $-0.78 | 8% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $4.0M | ADD |
| MORGAN STANLEY | $269.3K | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $100.5K | TRIM |
| BANK OF AMERICA CORP | $2.5K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 27, 2026 | BROADWOOD PARTNERS, | BUY | $913.1K |
| Apr 24, 2026 | BROADWOOD PARTNERS, | BUY | $137.1K |
| Apr 23, 2026 | BROADWOOD PARTNERS, | BUY | $982.0K |
| Apr 20, 2026 | BROADWOOD PARTNERS, | BUY | $158.0K |
| Apr 17, 2026 | BROADWOOD PARTNERS, | BUY | $143.3K |
4 institutional holders with $4.3M total value (576,323 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 526,675 | $4.0M | 91.4% | ADD +82.2% |
| 2 | MORGAN STANLEY | 35,913 | $269.3K | 6.2% | TRIM -42.3% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 13,400 | $100.5K | 2.3% | TRIM -43.2% |
| 4 | BANK OF AMERICA CORP /DE/ | 335 | $2.5K | 0.1% | ADD +29.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 62,208 | 35,913 | -42.3% | $269.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 23,600 | 13,400 | -43.2% | $100.5K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 15,365 | 2,714 | -82.3% | $9.0K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 265,457 | 483,771 | +82.2% | $1.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 26,100 | — | $78.8K | 2025-Q2 |
| UBS Group AG | DOUBLED | 2,654 | 15,365 | +478.9% | $46.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 441 | 570 | +29.3% | $1.7K | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 48,784 | — | $149.3K | 2025-Q1 |
| UBS Group AG | DOUBLED | 835 | 2,714 | +225.0% | $6.5K | 2024-Q4 |
4 unique insiders with 7 transactions. Net insider value: $5.7M ($5.7M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | BROADWOOD PARTNERS, L.P. | 10%+ Owner | BUY | 250,923 | $3.64 | $913.1K |
| Apr 24, 2026 | BROADWOOD PARTNERS, L.P. | 10%+ Owner | BUY | 38,880 | $3.53 | $137.1K |
| Apr 23, 2026 | BROADWOOD PARTNERS, L.P. | 10%+ Owner | BUY | 280,381 | $3.50 | $982.0K |
| Apr 20, 2026 | BROADWOOD PARTNERS, L.P. | 10%+ Owner | BUY | 40,690 | $3.88 | $158.0K |
| Apr 17, 2026 | BROADWOOD PARTNERS, L.P. | 10%+ Owner | BUY | 40,114 | $3.57 | $143.3K |
| Apr 16, 2026 | BROADWOOD PARTNERS, L.P. | 10%+ Owner | BUY | 102,057 | $3.45 | $351.7K |
| Mar 26, 2026 | Riggs Josh | CEO and President | M | 47,170 | $0.00 | $0.00 |
| Mar 26, 2026 | Liu James Yang | VP ACCT, Cntlr, Treasurer, PAO | M | 6,289 | $0.00 | $0.00 |
| Mar 26, 2026 | Riggs Josh | CEO and President | F | 12,310 | $4.11 | $50.6K |
| Mar 26, 2026 | Liu James Yang | VP ACCT, Cntlr, Treasurer, PAO | M | 6,289 | $0.00 | $0.00 |
| Mar 26, 2026 | Liu James Yang | VP ACCT, Cntlr, Treasurer, PAO | F | 2,578 | $4.11 | $10.6K |
| Mar 26, 2026 | Riggs Josh | CEO and President | M | 47,170 | $0.00 | $0.00 |
| Mar 26, 2026 | James Andrea S. | Chief Financial Officer | M | 28,302 | $0.00 | $0.00 |
| Mar 26, 2026 | James Andrea S. | Chief Financial Officer | F | 11,298 | $4.11 | $46.4K |
| Mar 26, 2026 | James Andrea S. | Chief Financial Officer | M | 28,302 | $0.00 | $0.00 |
| Feb 10, 2026 | BROADWOOD PARTNERS, L.P. | 10%+ Owner | BUY | 521,739 | $5.75 | $3.0M |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 70% buy across 10 analysts — 2 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$8.33 mean target (Feb 2026)
$4.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $5.85 |
| Target Low | $4.00 |
| Target Mean | $8.33 |
| Target Median | $9.00 |
| Target High | $12.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.23 | $-0.23 | 23.3% | — | — | $0.0B | -15.5% | 1 |
| Next Q 2026-09-30 |
$-0.18 | $-0.18 | $-0.18 | 22.9% | — | — | $0.0B | 109.2% | 1 |
| Current FY 2026-12-31 |
$-0.85 | $-0.85 | $-0.85 | — | — | 1↑ 0↓ | $0.0B | -47.0% | 1 |
| Next FY 2027-12-31 |
$-0.78 | $-0.78 | $-0.78 | 8.2% | — | 1↑ 0↓ | $0.0B | 259.8% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $0.000 | -0.230 |
| 30d ago | $0.000 | -0.230 |
| 60d ago | $0.000 | -0.230 |
| 90d ago | $0.000 | -0.230 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 17, 2026 | Lake Street | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| May 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Apr 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Mar 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Feb 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Jan 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
other
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
<p>NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced it will be highli
May 13, 2026
earnings
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
<p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter
May 13, 2026
earnings_calendar
IMDX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
IMDX Q1 2026 Earnings Scheduled — 2026-05-11
May 4, 2026
short_volume
Short Volume: IMDX — 60.5% short (0.4M / 0.6M)
Short: 371,270 | Exempt: 12,463 | TRF Vol: 613,864 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: IMDX — 59.8% short (0.4M / 0.7M)
Short: 402,675 | Exempt: 33,024 | TRF Vol: 673,264 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
earnings
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
<p>NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following lett
Mar 26, 2026
earnings_calendar
IMDX Q4 2025 Earnings After Market Close — 2026-03-26
Mar 13, 2026
other
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
<p>NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the <a href="ht